Patent Armory v. Southcoast Health System: 5-Patent Call Routing Dispute Dismissed in 45 Days
Patent Armory, Inc. asserted five patents covering intelligent call routing, telephony control, and auction-based entity matching against Southcoast Health System, Inc. in the District of Massachusetts. The parties jointly stipulated to dismiss all plaintiff claims with prejudice and all counterclaims without prejudice — closing the case in just 45 days.
A rapid exit: five-patent assertion ends in stipulated dismissal
Patent Armory, Inc. filed suit against Southcoast Health System, Inc. on February 17, 2025 in the U.S. District Court for the District of Massachusetts (Case No. 1:25-cv-10397), before Judge Mark G. Mastroianni. The complaint asserted five U.S. patents — US9456086B1, US10491748B1, US7269253B1, US7023979B1, and US10237420B1 — directed at intelligent communication routing systems, telephony control with intelligent call routing, and auction-based entity matching methods.
The case closed on April 3, 2025, just 45 days after filing. Under Federal Rule of Civil Procedure 41(a)(1)(A)(ii), both parties jointly stipulated to dismiss all of Patent Armory’s claims against Southcoast with prejudice, while all of Southcoast’s counterclaims against Patent Armory were dismissed without prejudice. The asymmetric dismissal structure is legally significant: Patent Armory is permanently barred from re-asserting these claims against Southcoast, whereas Southcoast retains the right to revive its counterclaims in future proceedings.
Resolution in 45 days — before any substantive briefing or claim construction — is consistent with an out-of-court settlement reached shortly after service, though the public record does not disclose any financial terms. The without-prejudice carve-out for counterclaims suggests Southcoast negotiated protective positioning, possibly reflecting a licence, covenant not to sue, or confidential payment. What drove the specific asymmetric dismissal structure remains undisclosed.
Filing to Case Dismissed in 45 days
45 days — well below the median 2–3 year patent case in D. Mass., suggesting early resolution
Asymmetric stipulated dismissal: what with and without prejudice means here
FRCP 41(a)(1)(A)(ii): stipulated dismissal without court order
Rule 41(a)(1)(A)(ii) allows parties to dismiss an action by filing a signed stipulation — no judicial approval required. The with-prejudice designation on Patent Armory’s claims is a final adjudication on the merits for res judicata purposes: Patent Armory cannot re-file these same claims against Southcoast in any court. This is a stronger finality than a standard voluntary dismissal.
Procedural — no merits rulingPatent Armory permanently barred from re-asserting these claims against Southcoast
Dismissal with prejudice functions as a final judgment against Patent Armory with respect to its infringement claims. Patent Armory surrendered the right to re-litigate the same five patents against Southcoast. This outcome typically signals either a negotiated resolution — such as a licence or lump-sum payment — or a decision that continued litigation was not commercially viable against this particular defendant.
Claims extinguishedSouthcoast’s counterclaims survive: without-prejudice carve-out preserved
Southcoast Health System secured dismissal of its counterclaims without prejudice, meaning those claims remain available for future assertion. This is an unusual and strategically significant concession by Patent Armory. It suggests Southcoast insisted on retaining its counterclaim rights — potentially declaratory judgment of non-infringement or invalidity — as a condition of settling, providing ongoing leverage.
Counterclaims preservedPAE assertion against healthcare IT: a 45-day exit signals rapid risk calculus
Patent assertion entities targeting healthcare system operators with legacy telephony and routing infrastructure face a high-friction enforcement environment. Southcoast’s retention of Fish & Richardson — a specialist patent litigation firm — may have signalled a credible invalidity threat. Other health systems operating similar intelligent call routing platforms should monitor Patent Armory’s remaining enforcement activity against the same patent family.
Healthcare IT enforcement riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Patent Armory, Inc. | Company | Patent assertion entity — holder of US9456086B1 and 4 further call routing patentsSearch in Eureka ↗ |
| Defendant | Southcoast Health System, Inc. | Company | Regional health system operator based in MassachusettsSearch in Eureka ↗ |
| Plaintiff counsel | Christopher E. Hanba | Attorney | Counsel for Patent Armory, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Dickinson Wright PLLC | Law Firm | Representing Patent Armory, Inc.Search in Eureka ↗ |
| Defendant counsel | Philip K. Chen | Attorney | Counsel for Southcoast Health System, Inc.Search in Eureka ↗ |
| Defendant law firm | Fish & Richardson PC (Bos) | Law Firm | Representing Southcoast Health System, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Mark G. Mastroianni | Judge | Massachusetts District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation’s asymmetric structure — plaintiff’s claims dismissed with prejudice, defendant’s counterclaims dismissed without prejudice — is the operative legal feature. With-prejudice dismissal under Rule 41(a)(1)(A)(ii) carries res judicata effect, permanently foreclosing Patent Armory from re-asserting these five patents against Southcoast. The without-prejudice carve-out for counterclaims is atypical and suggests Southcoast negotiated protective leverage as a condition of resolution. No merits determination was made on infringement, validity, or claim scope.
US9456086B1 — Intelligent communication routing system and method
The five asserted patents — US9456086B1, US10491748B1, US7269253B1, US7023979B1, and US10237420B1 — cover a range of communication routing technologies. Application dates span from 2003 (US10/385389) through 2017 (US15/856729), reflecting a portfolio that evolved across multiple technology generations. The core technical subject matter encompasses intelligent call routing logic, telephony system control, and auction-based entity matching algorithms applied to inbound communication flows — technology directly relevant to call centre and patient communications infrastructure.
For healthcare operators, this portfolio is strategically significant because intelligent call routing is deeply embedded in patient-facing communications platforms, appointment scheduling systems, and nurse call infrastructure. The breadth of the portfolio — spanning both early-generation telephony control patents and more recent routing method patents — suggests Patent Armory may assert these patents against a range of health system defendants. Organisations running Avaya, Cisco, or cloud-based CCaaS platforms for patient communications should assess exposure across the full family.
Should you run an FTO against US9456086B1 and the Patent Armory call routing portfolio?
Any organisation operating intelligent call routing, IVR systems, or telephony control infrastructure in a healthcare setting should treat this case as a trigger for FTO review. Patent Armory has now established a litigation record in D. Mass. against a regional health system, and the with-prejudice dismissal does not resolve the underlying validity or scope of the five asserted patents — they remain in force and available for assertion against other defendants.
PatSnap Eureka’s FTO Search Agent can map the claim scope of all five Patent Armory patents against your specific communications stack, identify prior art that may support invalidity arguments, and flag related continuation or continuation-in-part applications that could extend enforcement risk. Run a targeted FTO before deploying or upgrading patient-facing routing or call management platforms.
Run a freedom-to-operate analysis on US9456086B1 to assess your product’s exposure
Run FTO in Eureka →Similar intelligent call routing patent cases in U.S. District Courts
Explore comparable patent assertion actions involving intelligent call routing and telephony control patents filed in Massachusetts District Court and related federal venues.
What this case signals for the healthcare IT call routing IP landscape
A five-patent assertion resolved in 45 days with asymmetric prejudice terms reveals the enforcement calculus facing PAEs in the healthcare sector.
With-prejudice dismissal after 45 days: settlement is the most likely driver
Cases filed and dismissed this quickly — before any substantive court activity — almost invariably reflect a private resolution. Patent Armory’s acceptance of with-prejudice dismissal on its own claims while allowing Southcoast’s counterclaims to survive without prejudice is consistent with a negotiated licence or covenant not to sue rather than a pure capitulation.
Healthcare operators: Fish & Richardson defence posture may deter PAE claims
Southcoast’s instruction of Fish & Richardson PC, a top-tier patent litigation firm, likely signalled a robust invalidity and non-infringement defence. Health systems facing PAE assertions over communications infrastructure should assess whether a credible early defence posture accelerates resolution on more favourable terms.
Patent v Southcoast — key questions answered
Dismissal with prejudice under FRCP 41(a)(1)(A)(ii) means Patent Armory’s infringement claims against Southcoast are permanently extinguished. Patent Armory cannot re-file the same claims based on the same five patents against Southcoast in any court. The ruling carries res judicata effect but does not adjudicate patent validity or claim scope.
This asymmetric structure is consistent with a negotiated resolution in which Southcoast conditioned settlement on retaining its counterclaim rights — likely declaratory judgment of non-infringement or invalidity. Southcoast can revive those counterclaims in future proceedings. The structure suggests Southcoast had negotiating leverage, possibly through a credible invalidity defence.
Patent Armory asserted five patents: US9456086B1, US10491748B1, US7269253B1, US7023979B1, and US10237420B1. These cover intelligent communication routing systems, telephony control with intelligent call routing, and auction-based entity matching methods. Application dates range from 2003 to 2017.
The case resolved in 45 days — filing on February 17, 2025 and closing on April 3, 2025. This timeline is far shorter than the typical 2–3 year patent case and is consistent with early settlement negotiations conducted shortly after service. The public record does not disclose financial terms, licence terms, or a covenant not to sue.
The dismissal does not invalidate or limit the five asserted patents. They remain enforceable and available for assertion against other defendants. Healthcare organisations operating IVR, ACD, or intelligent routing infrastructure should consider an FTO analysis across the Patent Armory portfolio, particularly given the breadth of the application dates and claim scope spanning both early and recent routing technologies.
PatSnap Eureka searches patents and litigation data to answer instantly.